多发性骨髓瘤嵌合抗原受体T细胞治疗研究进展

Progress of chimeric antigen receptor T-cell therapy for multiple myeloma

嵌合抗原受体T细胞(CAR-T)在血液肿瘤治疗领域取得了突破性的成果。靶向κ免疫球蛋白轻链、CD19和B细胞成熟抗原(BCMA)的CAR-T疗法已被用于治疗难治复发多发性骨髓瘤(RRMM)患者,其中抗BCMA CAR-T疗效最佳。但由于BCMA阴性或阳性复发导致了较短的无进展生存(PFS)时间,对靶向BCMA的嵌合抗原受体(CAR)结构进行改进、双靶CAR-T以及CAR-T联合小分子药物等多项措施也成为目前CAR-T治疗RRMM的热点。

Chimeric antigen receptor T-cell(CAR-T)therapy has made a breakthrough in the treatment of hematological tumors.CAR-T therapy targeting kappa immunoglobulin light chain,CD19 and B-cell mature antigen(BCMA)have been used to treat relapsed/refractory MM(RRMM)patients,and the effect of anti-BCMA CAR-T is the best.However,the negative or positive recurrence of BCMA leads to a short progression-free survival(PFS),the improvement of the chimeric antigen receptor(CAR)structure targeted BCMA,dual-targeted CAR-T and CAR-T combined with small molecular drugs as well as other measures have become the focuses of CAR-T in the treatment of RRMM.